China National Accord Medicines (SZSE:000028) 3-Year EBITDA Growth Rate

: 6.10% (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

China National Accord Medicines's EBITDA per Share for the three months ended in Dec. 2023 was ¥1.28.

During the past 12 months, China National Accord Medicines's average EBITDA Per Share Growth Rate was 6.80% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was 6.10% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 13.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 13.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of China National Accord Medicines was 102.20% per year. The lowest was -48.60% per year. And the median was 21.40% per year.

Competitive Comparison

For the Medical Distribution subindustry, China National Accord Medicines's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

China National Accord Medicines 3-Year EBITDA Growth Rate Distribution

For the Medical Distribution industry and Healthcare sector, China National Accord Medicines's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where China National Accord Medicines's 3-Year EBITDA Growth Rate falls into.

China National Accord Medicines 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

China National Accord Medicines (SZSE:000028) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

China National Accord Medicines 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of China National Accord Medicines's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

China National Accord Medicines (SZSE:000028) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » China National Accord Medicines Corp Ltd (SZSE:000028) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

200028:China

Address

No. 15, Ba Gua Si 4th Road, Accord Pharmaceutical Building, Futian District, Guangdong Province, Shenzhen, CHN, 518029

Website

http://www.szaccord.com.cn

China National Accord Medicines Corp Ltd develops and manufactures pharmaceuticals in China. The company engaged in the wholesale of Chinese patent drugs, traditional Chinese medicines, chemical medicine preparations, antibiotics, biochemical drugs and cerebrovascular system drugs. It operates through the following segments: The Head office segment engages in investing and managing the business; The Pharmaceutical Distribution segment engages in the distribution of medicine and pharmaceutical products to customers, including hospitals, other distributors, retail drug stores, and clinics, and Retail pharmacy segment, which is managing the operation of Guoda Pharmacy. It generates maximum revenue from the Pharmaceutical Distribution segment.

China National Accord Medicines (SZSE:000028) Headlines

No Headlines